IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Polaris Venture Management Co. V, L.L.C.

Q2 2018 Holdings

Filed 2018-08-14 | 12 holdings | $183.5K | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Cardlytics, Inc.(CDLX)Common Stock14161W105$57.4K2,636,26231.3%
Fate Therapeutics, Inc.(FATE)Common Stock31189P102$28.0K2,473,18615.3%
Kala Pharmaceuticals, Inc.Common Stock483119103$25.5K1,857,58213.9%
Neuronetics, Inc.(STIM)Common Stock64131A105$21.9K824,76512.0%
Selecta Biosciences, Inc.(SELBUSD)Common Stock816212104$21.3K1,606,81311.6%
T2 Biosystems, Inc.Common Stock89853L104$14.3K1,841,9247.8%
Arsanis, Inc.Common Stock042873109$6.8K1,868,9573.7%
Trevena, Inc.Common Stock89532E109$3.0K2,053,5401.6%
Genocea Biosciences, Inc.Common Stock372427104$1.7K1,968,6060.9%
Atyr Pharma Inc.(LIFEUSD)Common Stock002120103$1.7K1,827,9920.9%
Pulmatrix, Inc.Common Stock74584P103$1.6K3,594,3810.9%
Dare Bioscience, Inc.(CERUEUR)Common Stock23666P101$382326,2430.2%